In the future, investigation with a model using cardiac-specific overexpression of METTL5 in vivo should be carried out to test the therapeutic potential of controlling mRNA translation via METTL5 in delaying cardiac hypertrophy and the progression of heart failure. Here, METTL5 is linked to heart failure.